THE ITALIAN JOB - RESEARCHERS ANALYSE RISING DEATH RATE OF THE VACCINATED SINCE C19 VAX ROLL-OUT

Five Italians have examined UK data from the ONS and have published their conclusions on Pubmed this February.

As they said in their introduction, "...the UK is perhaps the only country which has made publicly available all-cause mortality data by vaccination status..." and conclude that "...it would be desirable for other major countries to systematically collect all-cause mortality by vaccination status and, in the meantime, pending an in depth investigation, much greater caution should be exercised in promoting mass vaccination campaigns...."

Authors

Marco Alessandria 1, Giovanni Malatesta 2, Giovanni Di Palmo 3, Marco Cosentino 4, Alberto Donzelli 5

The authors, after analysing data and other studies came to five very important conclusions:

1. The data shows death rates among vaccinated people are increasing over time and have exceeded unvaccinated rates in several age groups.

   
   

2. The ONS data contains clear biases that artificially make vaccines appear safer than they are.

   
   

3. COVID-19 vaccines cannot logically protect against non-COVID deaths, yet the data initially shows this impossible effect.

   
   

4. This proves the dataset is flawed and underestimates risks for vaccinated individuals. Other countries must urgently collect and publish similar mortality data.

   
   

5. Until proper investigations are completed, mass vaccination campaigns should be halted due to these concerning mortality trends.

   
   

   
   

What is 'The Standardised Mortality Ratio' (SMR)? Is it the same as Excess Deaths?

The Standardised Mortality Ratio (SMR) is not exactly the same as excess deaths, though they are related concepts.

An SMR is a ratio that compares the observed number of deaths in a specific group to the expected number of deaths based on standard or reference population rates. It's calculated as:

SMR = (Observed deaths) / (Expected deaths)

When:

• SMR = 1: The observed deaths match what was expected

• SMR > 1: There are more deaths than expected

• SMR < 1: There are fewer deaths than expected

• 
  

For example, an SMR of 1.5 means there were 50% more deaths than expected in that group.

Excess deaths, on the other hand, typically refers to the absolute number of deaths beyond what would be expected under normal conditions during a specific time period.

In the context of this study, the researchers have been using SMRs to compare mortality rates between vaccinated and unvaccinated groups, with the unvaccinated group serving as the reference population.

THE STUDY

Abstract

Background: The mass vaccination campaign against COVID-19 has been commonly considered the best response to the global COVID-19 pandemic crisis. However, assessment of its real-world effect can be performed by analysis of all-cause mortality by vaccination status.

The UK is perhaps the only country which has made publicly available all-cause mortality data by vaccination status.

Methods: Data from April 2021 to May 2023 published by the UK Office for National Statistics (ONS) were retrospectively analyzed by age groups and vaccination status; the standardized mortality ratio (SMR) for all-cause and non-COVID-19 mortality was calculated against the corresponding unvaccinated groups.

Results: We found that across all age groups, all-cause mortality SMRs increased from a certain date, dependent on the age group. Across all age groups, all-cause mortality SMRs were initially much lower than 1.

However, due to their increase, by a certain date for the 18-39, 80-89 and 90+ age groups they exceeded the reference value. For the other age groups, the date at which the SMR would reach 1 can be predicted, provided the trend is maintained. Non-COVID-19 SMRs' trends were very similar.

Their initial values much lower than 1 are suggestive of significant biases in the ONS dataset, leading to underestimate the risks for the vaccinated people, as it is implausible that COVID-19 vaccines protect against non-COVID-19 deaths.

Conclusions: The increase over time in all-cause death SMRs in vaccinated people compared to unvaccinated, and their excess from the reference values for certain age groups, should be carefully considered to understand the underlying factors.

Furthermore, since the initial values of the SMRs are much lower than 1, we assume the presence of significant biases in the ONS dataset, leading to understimate the risks for the vaccinated people, as it is implausible that COVID-19 vaccines protect against non-COVID-19 deaths.

It would be desirable for other major countries to systematically collect all-cause mortality by vaccination status and, in the meantime, a pending indepth investigations, much greater caution should be exercised in promoting mass vaccination campaigns.

SEE THE STUDY HERE

References

1. Hussain Z: England and Wales have seen rise in excess deaths in 2022. BMJ. 2022;378:o2283. 10.1136/bmj.o2283 - DOI - PubMed

2. Deaths registered weekly in England and Wales, provisional: week ending 26 May 2023.(accessed on May 1, 2024). Reference Source

3. Schöley J, Aburto JM, Kashnitsky I, et al. : Life expectancy changes since COVID-19. Nat. Hum. Behav. 2022;6:1649–1659. 10.1038/s41562-022-01450-3 - DOI - PMC - PubMed

4. Mostert S, Hoogland M, Huibers M, et al. : Excess mortality across countries in the Western World since the COVID-19 pandemic: ‘Our World in Data’ estimates of January 2020 to December 2022. BMJ Public Health. 2024;2: e000282. 10.1136/bmjph-2023-000282 - DOI - PMC - PubMed

5. Deaths by vaccination status, England.(accessed on May 1, 2024). Reference Source

6. Our world in data - Share of people vaccinated against COVID-19, Apr 25, 2021.(accessed on May 1, 2024). Reference Source

7. Donzelli A, Malatesta G, Di Palmo G, et al. : All-Cause Mortality According to COVID-19 Vaccination Status: an analysis of the UK Office for National Statistics Public Data. Preprints. 2023;2023020414. 10.20944/preprints202302.0414.v1 - DOI

8. Soliani L: Statistica Applicata. Parma (PR), Italy: Uni. Nova;2008.

9. Norman G, Streiner D: Biostatistica. 2nd ed. Rozzano (MI): Casa Editrice Ambrosiana;2015.

10. Altman DG, Bland JM: How to obtain the P value from confidence interval from a. BMJ. 2011;343:d2304. 10.1136/bmj.d2304 - DOI - PubMed

11. Naing NN: Easy way to learn standardization: direct and indirect methods. Malays. J. Med. Sci. 2000 Jan;7(1):10–15. - PMC - PubMed

12. Acuti Martellucci C, Flacco ME, Soldato G, et al. : Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. Vaccines. 2022;10:662. 10.3390/vaccines10050662 - DOI - PMC - PubMed

13. Rosso A, Flacco ME, Soldato G, et al. : COVID-19 Vaccination Effectiveness in the General Population of an Italian Province: Two Years of Follo Up. Vaccines. 2023;11:1325. 10.3390/vaccines11081325 - DOI - PMC - PubMed

14. Berrino F, Donzelli A, Bellavite P, et al. : COVID-19 vaccination and all-cause and non-COVID-19 mortality. A revaluation of a study carried out in an Italian Province. Epidemiol. Prev. 2023 Nov-Dec;47(6):374–378. English. 10.19191/EP23.6.A643.075 - DOI - PubMed

15. Alessandria M, Malatesta GM, Berrino F, et al. : A Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian Province. Microorganisms. 2024;12:1343. 10.3390/microorganisms12071343 - DOI - PMC - PubMed

16. Pinsky PF, Miller A, Kramer BS, et al. : Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am. J. Epidemiol. 2007;165:874–881. 10.1093/aje/kwk075 - DOI - PubMed

17. Dormuth CR, Patrick AR, Shrank WH: Statin adherence and risk of accidents: a cautionary tale. Circulation. 2009;119:2051–2057. 10.1161/CIRCULATIONAHA.108.824151 - DOI - PMC - PubMed

18. Vestbo J, Anderson JA, Calverley PM, et al. : Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64:939–943. 10.1136/thx.2009.113662 - DOI - PubMed

19. Ladova K, Vlcek J, Vytrisalova M, et al. : Healthy adherer effect - the pitfall in the interpretation of the effect of medication adherence on health outcomes. J. Eval. Clin. Pract. 2014;20:111–116. 10.1111/jep.12095 - DOI - PubMed

20. Coronary Drug Project Research Group: Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N. Engl. J. Med. 1980;303:1038–1041. 10.1056/NEJM198010303031804 - DOI - PubMed

21. Simpson SH, Eurich DT, Majumdar SR, et al. : A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15. 10.1136/bmj.38875.675486.55 - DOI - PMC - PubMed

22. Jackson LA, Jackson ML, Nelson JC, et al. : Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int. J. Epidemiol. 2006;35:337–344. 10.1093/ije/dyi274 - DOI - PubMed

23. Horwitz RI, Viscoli CM, Berkman L, et al. : Treatment adherence and risk of death after a myocardial infarction. Lancet. 1990;336:542–545. 10.1016/0140-6736(90)92095-Y - DOI - PubMed

24. Furst T, Straka R, Janosek J: Healthy vaccinee effect: a bias not to be forgotten in observational studies on COVID-19 vaccine effectiveness. Pol. Arch. Intern. Med. 2024 Feb 28;134(2):16634. 10.20452/pamw.16634 - DOI - PubMed

25. Fürst T, Bazalová A, Fryčák T, et al. : Does the healthy vaccinee bias rule them all? Association of COVID-19 vaccination status and all-cause mortality from an analysis of data from 2.2 million individual health records. Int. J. Infect. Dis. 2024 May;142:106976. 10.1016/j.ijid.2024.02.019 - DOI - PubMed

26. McCarthy NL, Weintraub E, Vellozzi C, et al. : Mortality rates and cause-of-death patterns in a vaccinated population. Am. J. Prev. Med. 2013 Jul;45(1):91–97. 10.1016/j.amepre.2013.02.020 - DOI - PubMed

27. Redelmeier DA, Wang J, Thiruchelvam D: COVID Vaccine Hesitancy and Risk of a Traffic Crash. Am. J. Med. 2023;136:153–162.e5. 10.1016/j.amjmed.2022.11.002 - DOI - PMC - PubMed

28. Remschmidt C, Wichmann O, Harder T: Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: A systematic review. BMC Infect. Dis. 2015;15:429. 10.1186/s12879-015-1154-y - DOI - PMC - PubMed

29. Eythorsson E, Runolfsdottir HL, Ingvarsson RF, et al. : Rate of SARS-CoV-2 Reinfection During an Omicron Wave in Iceland. JAMA Netw. Open. 2022;5(8):e2225320. 10.1001/jamanetworkopen.2022.25320 - DOI - PMC - PubMed

30. Tseng HF, Ackerson BK, Bruxvoort KJ, et al. : Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat. Commun. 2023;14:189. 10.1038/s41467-023-35815-7 - DOI - PMC - PubMed

31. Chemaitelly H, Ayoub HH, Tang P, et al. : Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. Lancet Infect. Dis. 2023 Jul;23(7):816–827. 10.1016/S1473-3099(23)00058-0 - DOI - PMC - PubMed

32. Tamandjou C, Auvigne V, Schaeffer J, et al. : Effectiveness of second booster compared to first booster and protection conferred by previous SARS-CoV-2 infection against symptomatic Omicron BA.2 and BA.4/5 in France. Vaccine. 2023 Apr 24;41(17):2754–2760. 10.1016/j.vaccine.2023.03.031 - DOI - PMC - PubMed

33. Shrestha NK, Burke PC, Nowacki AS, et al. : Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine. Open Forum Infect. Dis. 2023 Apr 19;10(6):ofad209. 10.1093/ofid/ofad209 - DOI - PMC - PubMed

34. Qassim SH, Chemaitelly H, Ayoub HH, et al. : Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study. EClinicalMedicine. 2023 Jul 20;62:102102. 10.1016/j.eclinm.2023.102102 - DOI - PMC - PubMed

35. Chalupka A, Richter L, Chakeri A, et al. : Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria. Eur. J. Clin. Investig. 2024 Mar;54(3):e14136. 10.1111/eci.14136 - DOI - PMC - PubMed

36. Shrestha NK, Burke PC, Nowacki AS, et al. : Risk of Coronavirus Disease 2019 (COVID-19) among those up-to-date and not up-to-date on COVID-19 vaccination by US CDC criteria. PLoS One. 2023 Nov 8;18(11):e0293449. 10.1371/journal.pone.0293449 - DOI - PMC - PubMed

37. Wang H, Xu Q, Zhao C, et al. : An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy. J. Immunother. Cancer. 2020 Aug;8(2):e000661. 10.1136/jitc-2020-000661 - DOI - PMC - PubMed

38. Uversky VN, Redwan EM, Makis W, et al. : IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines (Basel). 2023 May 17;11(5):991. 10.3390/vaccines11050991 - DOI - PMC - PubMed

39. Alessandria M: Supplementary material. Zenodo. 2024. 10.5281/zenodo.13080361 - DOI

40. : Excess mortality across countries in the Western World since the COVID-19 pandemic: ‘Our World in Data’ estimates of January 2020 to December 2022. BMJ Public Health .2024;2(1) : 10.1136/bmjph-2023-000282 10.1136/bmjph-2023-000282 - DOI - PMC - PubMed